Photo of Paolo Tarantino from X
Nov 27, 2023, 17:43
Paolo Tarantino: Can we get rid of the anthracyclines from the KN522 regimen?
Paolo Tarantino, Researcher at the European Institute of Oncology and clinical research fellow at the Dana-Farber Cancer Institute, shared a post on X/Twitter:
“Can we get rid of the anthracyclines from the KN522 regimen? The ph2 NeoPACT trial is published on JAMA Oncology: neoadjuvant Carbo/Docetaxel/Pembro x6 led to a pCR rate of 58% and 3y EFS of 86% for stage I-III TNBC. Confirmatory phase 3 SCARLET trial ongoing.”
For the article click here.
Source: Paolo Tarantino/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46